(MedPage Today) — CHICAGO — Patients who skipped maintenance therapy after a complete response to upfront treatment with a PD-1 inhibitor lived just as long as those who had 3 years of maintenance, data from a cohort study that compared nonsurgical…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
